it would definitely be worth clarifying for sure. If it is in fact the LGND BACE program, suffice to say LGND would look a bit intriguing to me.
What do you mean it would make LGND a bit more intriguing. I thought it already was .
For what its worth I think it is the current molecule. At last years (2010) R&D day I thought they talked about it and checked the slide presentation and slide 37 talks about it in Phase 1 with Phase 2 expected to in late 2010 (that is why I guess its the same molecule but don't invest on my guess ). A word of caution its a long ways off as I believe the trial they said Merck was planning was in earlier stage patients and would be multi-year treatment duration.